|
|
Gene Symbol |
VEGFA |
|
Aliases |
MVCD1, VEGF, VPF |
|
Entrez Gene ID |
|
|
Gene Name |
Vascular endothelial growth factor A |
|
Chromosomal Location |
6p21.1 |
|
HGNC ID |
|
|
Summary |
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
NM_001025366.3, NM_003376.6, NM_001025367.3, NM_001025368.3, NM_001025369.3, NM_001025370.3, NM_001033756.3, NM_001171622.2, NM_001171623.1, NM_001171624.1, NM_001171625.1, NM_001171626.1, NM_001171627.1, NM_001171628.1, NM_001171629.1, NM_001171630.1, NM_001204384.1, NM_001204385.2, NM_001287044.2, NM_001317010.1 |
|
e!Ensembl
Gene |
|
|
Transcript |
ENST00000372067, ENST00000672860, ENST00000324450, ENST00000417285, ENST00000413642, ENST00000372055, ENST00000482630, ENST00000425836, ENST00000372064, ENST00000372077, ENST00000519767, ENST00000520948, ENST00000523873, ENST00000523950, ENST00000457104, ENST00000518689, ENST00000523125, ENST00000518824, ENST00000230480, ENST00000520265, ENST00000611736, ENST00000621747, ENST00000617771, ENST00000640653, ENST00000615393, ENST00000640482, ENST00000640499 |
|
Protein |
ENSP00000361137, ENSP00000500082, ENSP00000317598, ENSP00000388663, ENSP00000389864, ENSP00000361125, ENSP00000421561, ENSP00000388465, ENSP00000361134, ENSP00000361148, ENSP00000430594, ENSP00000428321, ENSP00000430479, ENSP00000429643, ENSP00000409911, ENSP00000430829, ENSP00000429008, ENSP00000430002, ENSP00000230480, ENSP00000429592, ENSP00000478570, ENSP00000483241, ENSP00000484284, ENSP00000492199, ENSP00000478034, ENSP00000492800, ENSP00000492413
|
|
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0000122 |
Biological process |
Negative regulation of transcription by RNA polymerase II |
IDA |
18093989 |
GO:0001525 |
Biological process |
Angiogenesis |
IBA |
21873635 |
GO:0001525 |
Biological process |
Angiogenesis |
IDA |
11427521, 21771332 |
GO:0001570 |
Biological process |
Vasculogenesis |
TAS |
15015550 |
GO:0001666 |
Biological process |
Response to hypoxia |
IBA |
21873635 |
GO:0001666 |
Biological process |
Response to hypoxia |
IDA |
16490744 |
GO:0001934 |
Biological process |
Positive regulation of protein phosphorylation |
IBA |
21873635 |
GO:0001934 |
Biological process |
Positive regulation of protein phosphorylation |
IDA |
18386220, 19033661 |
GO:0001938 |
Biological process |
Positive regulation of endothelial cell proliferation |
IBA |
21873635 |
GO:0001938 |
Biological process |
Positive regulation of endothelial cell proliferation |
IDA |
9202027, 10022831, 12714610, 16489009, 18386220, 18577655, 20497126 |
GO:0002040 |
Biological process |
Sprouting angiogenesis |
IBA |
21873635 |
GO:0002042 |
Biological process |
Cell migration involved in sprouting angiogenesis |
IDA |
18059339, 20660291 |
GO:0002092 |
Biological process |
Positive regulation of receptor internalization |
IDA |
20660291 |
GO:0002687 |
Biological process |
Positive regulation of leukocyte migration |
TAS |
1312256 |
GO:0007399 |
Biological process |
Nervous system development |
TAS |
15351965 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IDA |
7929439 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IMP |
26268439 |
GO:0008360 |
Biological process |
Regulation of cell shape |
IDA |
7929439, 10527820 |
GO:0010595 |
Biological process |
Positive regulation of endothelial cell migration |
IDA |
10022831, 19033661 |
GO:0010628 |
Biological process |
Positive regulation of gene expression |
IDA |
18386220 |
GO:0010629 |
Biological process |
Negative regulation of gene expression |
IDA |
28977001 |
GO:0010749 |
Biological process |
Regulation of nitric oxide mediated signal transduction |
IDA |
16150726 |
GO:0030224 |
Biological process |
Monocyte differentiation |
IDA |
21149635 |
GO:0030225 |
Biological process |
Macrophage differentiation |
IDA |
21149635 |
GO:0030335 |
Biological process |
Positive regulation of cell migration |
IDA |
7929439, 17470632 |
GO:0030949 |
Biological process |
Positive regulation of vascular endothelial growth factor receptor signaling pathway |
IDA |
1312256, 7929439 |
GO:0031334 |
Biological process |
Positive regulation of protein complex assembly |
IDA |
16489009, 19033661 |
GO:0031954 |
Biological process |
Positive regulation of protein autophosphorylation |
IDA |
20497126 |
GO:0032147 |
Biological process |
Activation of protein kinase activity |
IDA |
18059339, 20497126 |
GO:0032793 |
Biological process |
Positive regulation of CREB transcription factor activity |
IDA |
20497126 |
GO:0033138 |
Biological process |
Positive regulation of peptidyl-serine phosphorylation |
IDA |
18440775, 20497126 |
GO:0035148 |
Biological process |
Tube formation |
IDA |
19033661 |
GO:0035767 |
Biological process |
Endothelial cell chemotaxis |
IDA |
18440775 |
GO:0035924 |
Biological process |
Cellular response to vascular endothelial growth factor stimulus |
IDA |
18440775, 20497126 |
GO:0038033 |
Biological process |
Positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway |
IDA |
18440775, 20497126, 21245381 |
GO:0038084 |
Biological process |
Vascular endothelial growth factor signaling pathway |
IBA |
21873635 |
GO:0038091 |
Biological process |
Positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway |
IDA |
17470632 |
GO:0042531 |
Biological process |
Positive regulation of tyrosine phosphorylation of STAT protein |
IDA |
19390056 |
GO:0043066 |
Biological process |
Negative regulation of apoptotic process |
IMP |
10066377, 11461089 |
GO:0043154 |
Biological process |
Negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
IDA |
18386220 |
GO:0043406 |
Biological process |
Positive regulation of MAP kinase activity |
IDA |
18440775 |
GO:0043536 |
Biological process |
Positive regulation of blood vessel endothelial cell migration |
IDA |
9202027, 18440775, 20497126 |
GO:0045766 |
Biological process |
Positive regulation of angiogenesis |
IBA |
21873635 |
GO:0045766 |
Biological process |
Positive regulation of angiogenesis |
IDA |
18440775, 18577655, 19033661, 20497126 |
GO:0045766 |
Biological process |
Positive regulation of angiogenesis |
IMP |
18275976 |
GO:0045785 |
Biological process |
Positive regulation of cell adhesion |
IDA |
19674970 |
GO:0045944 |
Biological process |
Positive regulation of transcription by RNA polymerase II |
IDA |
18059339 |
GO:0045944 |
Biological process |
Positive regulation of transcription by RNA polymerase II |
IMP |
18093989 |
GO:0048010 |
Biological process |
Vascular endothelial growth factor receptor signaling pathway |
IBA |
21873635 |
GO:0048010 |
Biological process |
Vascular endothelial growth factor receptor signaling pathway |
IDA |
21245381 |
GO:0050731 |
Biological process |
Positive regulation of peptidyl-tyrosine phosphorylation |
IDA |
10022831, 16489009, 21245381 |
GO:0050918 |
Biological process |
Positive chemotaxis |
IDA |
20497126 |
GO:0050927 |
Biological process |
Positive regulation of positive chemotaxis |
IDA |
7929439, 12744932 |
GO:0050930 |
Biological process |
Induction of positive chemotaxis |
IBA |
21873635 |
GO:0050930 |
Biological process |
Induction of positive chemotaxis |
NAS |
12744932 |
GO:0051272 |
Biological process |
Positive regulation of cellular component movement |
IDA |
10527820, 12744932 |
GO:0051894 |
Biological process |
Positive regulation of focal adhesion assembly |
IDA |
16489009 |
GO:0060754 |
Biological process |
Positive regulation of mast cell chemotaxis |
IBA |
21873635 |
GO:0061419 |
Biological process |
Positive regulation of transcription from RNA polymerase II promoter in response to hypoxia |
IMP |
19652095 |
GO:0071456 |
Biological process |
Cellular response to hypoxia |
IDA |
10575000 |
GO:0090037 |
Biological process |
Positive regulation of protein kinase C signaling |
IDA |
18059339 |
GO:0090050 |
Biological process |
Positive regulation of cell migration involved in sprouting angiogenesis |
IDA |
20551324 |
GO:0090050 |
Biological process |
Positive regulation of cell migration involved in sprouting angiogenesis |
IGI |
24844779 |
GO:0090050 |
Biological process |
Positive regulation of cell migration involved in sprouting angiogenesis |
IMP |
24865854 |
GO:0097533 |
Biological process |
Cellular stress response to acid chemical |
IDA |
26299712 |
GO:0120162 |
Biological process |
Positive regulation of cold-induced thermogenesis |
ISS |
26683794 |
GO:1900086 |
Biological process |
Positive regulation of peptidyl-tyrosine autophosphorylation |
IDA |
20660291 |
GO:1900745 |
Biological process |
Positive regulation of p38MAPK cascade |
IDA |
18386220 |
GO:1901727 |
Biological process |
Positive regulation of histone deacetylase activity |
IDA |
20497126 |
GO:1903572 |
Biological process |
Positive regulation of protein kinase D signaling |
IDA |
20497126 |
GO:1903589 |
Biological process |
Positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis |
IGI |
24844779 |
GO:1903672 |
Biological process |
Positive regulation of sprouting angiogenesis |
IDA |
26299712 |
GO:1903672 |
Biological process |
Positive regulation of sprouting angiogenesis |
IGI |
25251394 |
GO:0005615 |
Cellular component |
Extracellular space |
IBA |
21873635 |
GO:0005615 |
Cellular component |
Extracellular space |
IDA |
9202027, 16490744 |
GO:0005737 |
Cellular component |
Cytoplasm |
IDA |
17082651 |
GO:0009986 |
Cellular component |
Cell surface |
IDA |
17470632 |
GO:0030141 |
Cellular component |
Secretory granule |
IDA |
17082651 |
GO:0031012 |
Cellular component |
Extracellular matrix |
NAS |
14570917 |
GO:0001968 |
Molecular function |
Fibronectin binding |
IDA |
14570917 |
GO:0005125 |
Molecular function |
Cytokine activity |
IDA |
18440775 |
GO:0005161 |
Molecular function |
Platelet-derived growth factor receptor binding |
IPI |
17470632 |
GO:0005172 |
Molecular function |
Vascular endothelial growth factor receptor binding |
IBA |
21873635 |
GO:0005172 |
Molecular function |
Vascular endothelial growth factor receptor binding |
IPI |
10471394, 11513746 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
9393862, 10543948, 16763549, 17222790, 20660291, 22020326, 23374253, 23583373 |
GO:0008083 |
Molecular function |
Growth factor activity |
IBA |
21873635 |
GO:0008083 |
Molecular function |
Growth factor activity |
IDA |
9202027, 20497126 |
GO:0008201 |
Molecular function |
Heparin binding |
IDA |
15001987 |
GO:0008201 |
Molecular function |
Heparin binding |
IMP |
14570917 |
GO:0042056 |
Molecular function |
Chemoattractant activity |
IBA |
21873635 |
GO:0042056 |
Molecular function |
Chemoattractant activity |
IDA |
17082651, 18059339, 18440775, 20497126, 21245381 |
GO:0042802 |
Molecular function |
Identical protein binding |
IPI |
12207021, 25132001 |
GO:0043183 |
Molecular function |
Vascular endothelial growth factor receptor 1 binding |
IBA |
21873635 |
GO:0043183 |
Molecular function |
Vascular endothelial growth factor receptor 1 binding |
IPI |
1312256 |
GO:0043184 |
Molecular function |
Vascular endothelial growth factor receptor 2 binding |
IBA |
21873635 |
GO:0043184 |
Molecular function |
Vascular endothelial growth factor receptor 2 binding |
IPI |
1417831, 10022831, 20660291 |
GO:0046982 |
Molecular function |
Protein heterodimerization activity |
IDA |
8702615 |
GO:0048018 |
Molecular function |
Receptor ligand activity |
IPI |
20660291 |
GO:0050840 |
Molecular function |
Extracellular matrix binding |
IC |
14570917 |
|
Protein Information |
|
Protein Name |
Vascular endothelial growth factor A, vascular endothelial growth factor A121, vascular endothelial growth factor A165, vascular permeability factor |
|
Function |
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). |
|
|
|
NP_001020537.2, NP_003367.4, NP_001020538.2, NP_001020539.2, NP_001020540.2, NP_001020541.2, NP_001028928.1, NP_001165093.1, NP_001165094.1, NP_001165095.1, NP_001165096.1, NP_001165097.1, NP_001165098.1, NP_001165099.1, NP_001165100.1, NP_001165101.1, NP_001191313.1, NP_001191314.1, NP_001273973.1, NP_001303939.1
|
|
UniProt |
|
|
PDB |
5O4E, 6BFT, 2QR0, 3BDY, 4QAF, 4DEQ, 5DN2, 1BJ1, 1CZ8, 1FLT, 1KAT, 1KMX, 1MJV, 1MKG, 1MKK, 1QTY, 1TZH, 1TZI, 1VGH, 1VPF, 1VPP, 2FJG, 2FJH, 2VGH, 2VPF, 3P9W, 3QTK, 3S1B, 3S1K, 3V2A, 4GLN, 4GLS, 4KZN, 4WPB, 4ZFF, 5FV1, 5FV2, 5HHC, 5HHD, 5T89, 6D3O |
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000357255 |
|
P02818 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Blood Disorders |
Thrombotic Microangiopathies |
|
Cardiovascular Diseases |
Arteriosclerosis |
|
Heart Failure |
|
Myocardial Ischemia |
|
Retinal Vein Occlusion |
|
Myocardial Failure |
|
Atherosclerosis |
|
Retinal Vein Thrombosis |
|
Cardiovascular Abnormalities |
|
Heart Diseases |
|
Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Skeletal Dysplasia |
|
Schwartz-Jampel Syndrome |
|
Melnick-Needles Syndrome |
|
Van Buchem disease |
|
Digestive System Diseases |
Gastric ulcer |
|
Liver Fibrosis |
|
Portal Hypertension |
|
Liver Failure |
|
Liver Cirrhosis |
|
Cruveilhier-Baumgarten Syndrome |
|
Endocrine System Diseases |
Diabetes Mellitus |
|
Glomerulosclerosis |
|
PCOS |
|
Eye Diseases |
Retinal Diseases |
|
Irvine-Gass Syndrome |
|
Macular retinal edema |
|
Macular Degeneration |
|
Diabetic Retinopathy |
|
Corneal Neovascularization |
|
Macular Edema |
|
Immune System Diseases |
Rheumatoid Arthritis |
|
Neoplasms |
Myeloid Leukemia |
|
Rhabdomyoma |
|
Prostate cancer |
|
Glioblastoma |
|
Adenocarcinoma |
|
Brain Neoplasms |
|
Neck Neoplasms |
|
Osteosarcoma |
|
Urinary Tract Cancer |
|
Head Neoplasms |
|
Endometrial Cancer |
|
Head and Neck Neoplasms |
|
Cribriform Carcinoma |
|
Leukemia |
|
Colonic Neoplasms |
|
Carcinoma |
|
Lung Cancer |
|
Gliosarcoma |
|
Digestive Track Neoplasms |
|
Genitourinary Cancer |
|
Neoplasms |
|
Cervical Cancer |
|
Renal Cancer |
|
Hemangioma |
|
Pancreatic Neoplasm |
|
Glioblastoma Multiforme |
|
Vulvar Cancer |
|
Nervous System Diseases |
Status Epilepticus |
|
Ischemic Encephalopathy |
|
Epilepsy |
|
Petit mal status |
|
Nutritional and Metabolic Diseases |
Gluocose Intolerance |
|
Psychiatric/Brain disorders |
Mental Depression |
|
Mood Disorders |
|
Senile Dementia |
|
Memory Disorders |
|
Learning Disorders |
|
Alzheimer Disease |
|
Bipolar Disorder |
|
Schizophrenia |
|
Obstructive Sleep Apnea |
|
Renal Disorder |
Kidney Failure |
|
Kidney Insufficiency |
|
Diabetic Nephropathy |
|
Reproductive disorders |
Preeclampsia |
|
Respiratory Tract Diseases |
Asthma |
|
Chronic Bronchitis |
|
Skin and Connective Tissue Diseases |
Psoriasis |
|
Dermatitis |
|
Pustulosis |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
Drd2,VEGFR-2 |
Ovarian hyperstimulation syndrome |
|
Rotterdam criteria |
Related
|
|
Decreased dopaminergic tone as well as deregulated Drd2 signaling might explain higher VEGF and vascularization leading to increased ovarian hyperstimulation syndrome risk in PCOS |
|
IGF-1 |
Ovarian hyperstimulation syndrome |
|
Basedon clinical maifestations and ultrasound criteria |
Related
|
|
Higher serum levels of VEGF and IGF-1 may explain the increased vascularity that was demonstrated by Doppler blood flow measurements in PCOS |
|
Angiopoietin-2 |
Oxidative stress |
|
Rotterdam criteria |
Related
|
|
Concentrations of VEGF were higher among obese subjects with PCOS |
|
|
Ovarian hyperstimulation syndrome |
|
|
Related
|
University of Pisa-Italy 30 PCOS patients and 20 controls undergoing In vitro fertilisation (IVF) |
The increase in VEGF bioactivity in PCOS patients undergoing IVF was not only because of increasing levels of VEGF but also to decreasing levels of its soluble receptor. |
|
|
|
Novel SNP at +9812 site, one known SNP at +13553 site, and one selected haplotype (ht4) |
Rotterdam criteria |
Related
|
Korean- 134 PCOS and 100 controls |
The study concludes that one novel SNP at +9812 site, one known SNP at +13553 site, and one selected haplotype in the VEGF gene have a high possibility of significant associations with the pathogenesis of PCOS in a Korean population |
|
BFGF |
Ovarian hyperstimulation |
|
|
Related
|
|
The present study revealed elevated levels of VEGF and bFGF in serum and follicular fluid in PCOS patients compared with controls |
|
|
|
|
|
Related
|
|
VEGF levels in women with PCOS are higher than in normal women, and ovarian drilling does not affect these levels |
|
|
Ovarian hyperstimulation syndrome |
|
Established US and clinical criteria (1985 and 1991) |
Related
|
|
The results support the role of VEGF as a mediator of OHSS and establish a possible link between VEGF, OHSS, and PCO. |
|
|
Ovarian hyperstimulation syndrome |
|
|
Related
|
|
Higher serum concentrations of VEGF in women with PCO and PCOS may relate to the increased vascularity that underlies the increased blood flow demonstrated by Doppler blood flow velocity measurements in these women. |
|
IGF-1 |
|
|
|
Related
|
|
Higher serum levels of VEGF and IGF-1 in PCOS women may be related to the increased vascularity that underlies the increased blood flow demonstrated by Doppler blood flow measurements in these women. |
|
CRP,homocysteine,PAI-1,Lp(a),TNF-alpha,IL-6,ADMA,endothelin-1 (ET-1) and fibrinogen |
Cardiovascular disease |
|
NIH, Rotterdam and/ or other compatable criteria |
Related
|
|
Women with PCOS demonstrated significantly elevated VEGF levels |
|
|
|